|

ONC206 Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: DRD2 antagonist/ClpP agonist, antagonist of dopamine receptor D2 (DRD2) /human mitochondrial caseinolytic protease P (ClpP)ClpP Agonist

Pipeline

Phase 1: 2Phase 2: 1

Top Sponsors

  • Jazz Pharmaceuticals2
  • Sabine Mueller, MD, PhD1

Indications

  • Cancer3
  • Glioblastoma2
  • PCPG1
  • Advanced Pheochromocytoma and Paraganglioma1
  • Choroid Plexus Neoplasms1

Los Angeles, California1 trial

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

UCLA

Phase 2

San Francisco, California1 trial

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

University of California, San Francisco

Phase 1

Bethesda, Maryland1 trial

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

National Institutes of Health

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.